TABLE 1.
Characteristics of patients with ILD associated with COVID‐19 vaccine
| Our case | Park 3 | Yoshifuji 4 | Miqdadi 5 | Piqueras 6 | Shimizu 7 | Shimizu 7 | Shimizu 7 | |
|---|---|---|---|---|---|---|---|---|
| Age/sex | 78/Female | 86/Male | 60/Male | 66/Male | 37/Male | 66/Male | 85/Male | 62/Male |
| Smoking | Never | Never | Ex‐smoker | — | — | Ex‐smoker | Ex‐smoker | Never |
| Underlying ILD | No | No | No | No | No | Yes | Yes | No |
| Onset | ||||||||
| Number of vaccinations | First, second | First | Second | First | Second | First | First | Second |
| Days after vaccination | 10, 9 | 2 | 3 | 1 | 1 | 2 | 4 | 3 |
| Re‐vaccination | Yes | No | — | — | — | No | Yes | — |
| KL‐6 (U/ml) | 919 | — | 800 | — | — | 1306 | 4084 | 297 |
| SP‐D (ng/ml) | 178 | — | 155 | — | — | 376 | 676 | 189 |
| BAL findings | ||||||||
| Macrophages (%) | 6 | — | 46.9 | — | — | 55 | 30.7 | — |
| Lymphocytes (%) | 79 | — | 31.3 | — | — | 42.3 | 62.7 | — |
| Neutrophils (%) | 1 | — | 21.9 | — | — | 1.7 | 0 | — |
| Eosinophils (%) | 14 | — | 0 | — | 60.3 | 1 | 6.7 | — |
| CD4/CD8 | 0.21 | — | 1.26 | — | — | 1.3 | 6.6 | — |
| Patterns of ILD | OP | — | — | AEP | AEP | — | — | — |
Abbreviations: AEP, acute eosinophilic pneumonia; BAL, bronchoalveolar lavage; COVID‐19, coronavirus disease; ILD, interstitial lung disease; KL‐6, Krebs von den Lungen 6 (normal range < 500 U/ml); OP, organizing pneumonia; SP‐D, surfactant protein D (normal range < 110 ng/ml).